Phaxiam: presents its 'ambitious' phage therapy strategy

(CercleFinance.com) - Phaxiam Therapeutics has presented its 'ambitious' development strategy, aimed at taking advantage of the rapidly evolving phage therapy market.


In this context, Phaxiam today organized a presentation webinar and a round table discussion.

In particular, the laboratory pointed out that there is a strong demand from doctors for phage therapy, a technique that enables pathogenic bacteria to be destroyed by viruses that are lethal to them, but without infecting the host.

Experts discussed the critical need for individualized treatments and the synergies between two approaches: the PTMP (Phages Therapy Medical Product) clinical model and IPT (Individualized Phage Therapy) magistral preparations.

Phaxiam plans to achieve revenues of 100 million euros in 2030 thanks to these two models, with operational profitability expected in 2027.


Copyright (c) 2024 CercleFinance.com. All rights reserved.